Roche’s Tecentriq as a first-line monotherapy helped certain people with advanced non-small cell lung cancer live longer compared with chemotherapy

    NEXT STORY
    Roche’s satralizumab significantly reduced relapse risk in second positive phase III study for neuromyelitis optica spectrum
    PREV STORY
    BeiGene Announces Clinical Data to Be Presented at the Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
    Subscribe to PM360
    Follow Us

    Experts on Call

    Get in touch with PM360 Experts On Call

    Ads

    You May Also Like

    Liquid Biopsy Market, 2024

    Dublin, March 27, 2018 (GLOBE NEWSWIRE) -- The "Liquid Biopsy Global Market - Forecast ...

    author_avatar
    NASDAQ Market News

    Cempra Announces Presentations at Upcoming Investor Conferences and Provides Merger Process Update

    CHAPEL HILL, N.C., Sept. 07, 2017 (GLOBE NEWSWIRE) -- Cempra, Inc. (Nasdaq:CEMP), a clinical-stage ...

    author_avatar
    NASDAQ Market News

    Asterias Receives Regulatory Clearance to Initiate Clinical Study of AST-VAC2 in Subjects with Early and Late Stage Non-Small Cell Lung Cancer

    FREMONT, Calif., Sept. 26, 2017 (GLOBE NEWSWIRE) -- Asterias Biotherapeutics, Inc. (NYSE MKT:AST), a ...

    author_avatar
    NASDAQ Market News